Asianet Newsable on MSN
SLS stock snaps 2-day slide: Sellas’ SLS009 AML trial spotlights big pharma drug combo from ABBV, RHHBY and BMY
SLS009 traces back to Sellas’ 2022 GenFleet licensing deal, when the company obtained rights outside Greater China to GFH009, ...
Ashwin Kishtagari, MBBS, is Assistant Professor of Medicine in the division of hematology and oncology at Vanderbilt ...
Hosted on MSN
SLS stock sees worst day in over a month — but prediction market flashes 83% odds for November AML trial success
・The clinical-trials prediction market priced “YES” contracts on a positive GPS AML result at $0.83, implying an 83% probability of success. ・GPS, or galinpepimut-S, is being tested as AML maintenance ...
Ivosidenib plus azacitidine significantly prolongs median overall survival in patients with IDH1-mutated acute myeloid leukemia (AML), with a median overall survival of 29.3 months versus 7.9 months ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results